Home » Stocks » XAIR

Beyond Air, Inc. (XAIR)

Stock Price: $5.45 USD -0.06 (-1.09%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 111.65M
Revenue (ttm) 530,216
Net Income (ttm) -22.91M
Shares Out 17.61M
EPS (ttm) -1.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $5.45
Previous Close $5.51
Change ($) -0.06
Change (%) -1.09%
Day's Open 5.54
Day's Range 5.11 - 5.60
Day's Volume 240,113
52-Week Range 4.65 - 8.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Award will help fund the development of high concentration nitric oxide (NO) for Nontuberculous Mycobacteria (NTM) pulmonary disease, which disproportionately affects cystic fibrosis (CF) patients

2 months ago - GlobeNewsWire

Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -6.45% and -25.50%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Beyond Air (NASDAQ:XAIR) moved lower in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 23.26% over the past year to ($0.33), which mis...

2 months ago - Benzinga

U.S. FDA reviewing premarket approval (PMA) submission for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN), as Company prepares for commercialization

2 months ago - GlobeNewsWire

Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Call scheduled for Tuesday, February 9th at 4:30 pm Eastern Time Call scheduled for Tuesday, February 9th at 4:30 pm Eastern Time

3 months ago - GlobeNewsWire

Beyond Air Offers Compelling Value Heading Into Its First Potential Product Approval

3 months ago - Seeking Alpha

GARDEN CITY, N.Y., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for th...

4 months ago - GlobeNewsWire

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q2 2021 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Potential to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinders creating im proved economics and safety in hospital setting

5 months ago - GlobeNewsWire

Call scheduled for Wednesday, November 11th at 4:30 pm Eastern Time Call scheduled for Wednesday, November 11th at 4:30 pm Eastern Time

5 months ago - GlobeNewsWire

Patients with pneumonia caused by any virus, including SARS-CoV-2, will be considered for enrollment

5 months ago - GlobeNewsWire

New in vivo data for colon cancer show anti-tumor immunity in 100% of mice

5 months ago - GlobeNewsWire

In vitro data support development of nitric oxide as a potential coronavirus therapy that acts within hours

5 months ago - GlobeNewsWire

150 ppm nitric oxide was statistically significant compared to both control and 85 ppm nitric oxide arms on the primary and key secondary endpoints

5 months ago - GlobeNewsWire

GARDEN CITY, N.Y., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for th...

6 months ago - GlobeNewsWire

GARDEN CITY, N.Y., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for...

7 months ago - GlobeNewsWire

GARDEN CITY, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for...

7 months ago - GlobeNewsWire

GARDEN CITY, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for ...

7 months ago - GlobeNewsWire

Heterogeneity in M. abscessus susceptibility to NO

8 months ago - GlobeNewsWire

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q1 2021 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Beyond Air Has Huge Long-Term Potential

8 months ago - Seeking Alpha

AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

8 months ago - Zacks Investment Research

Conference call at 8:30 a.m. ET Conference call at 8:30 a.m. ET

8 months ago - GlobeNewsWire

Shares of Beyond Air Inc (NASDAQ:XAIR) rose by 2.9% from the previous closing price.

9 months ago - Benzinga

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q4 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Reported positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary endpoints

9 months ago - GlobeNewsWire

Data demonstrate the ablation of solid tumors with nitric oxide

9 months ago - GlobeNewsWire

AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

10 months ago - Zacks Investment Research

GARDEN CITY, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for ...

10 months ago - GlobeNewsWire

Anticipate study start in June 2020 Anticipate study start in June 2020

10 months ago - GlobeNewsWire

High concentration nitric oxide (150 ppm) is statistically significant compared to both low concentration nitric oxide (85 ppm) and control arms on both the primary endpoint and the key secondary endp...

10 months ago - GlobeNewsWire

GARDEN CITY, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for t...

11 months ago - GlobeNewsWire

Food and Drug Administration (FDA) agrees to a trial using  the LungFit ™ system to treat COVID-19 patients

1 year ago - GlobeNewsWire

Prepared to test LungFit™ BRO in COVID-19 patients in a clinical study starting in April pending FDA approval of recently submitted IDE (investigational device exemption) Prepared to test LungFit™ BRO i...

1 year ago - GlobeNewsWire

Beyond Air Inc. XAIR, +17.05% said Monday that it submitted an investigational device exemption to the Food and Drug Administration (FDA) as it seeks authority to market its nitric oxide device to treat...

1 year ago - Market Watch

Beyond Air: Buy The Stock Ahead Of March 5 Analyst Day

1 year ago - Seeking Alpha

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q3 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

AIT Therapeutics, Inc. (XAIR) delivered earnings and revenue surprises of -30.30% and -45.39%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Ni...

1 year ago - GlobeNewsWire

GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Ni...

1 year ago - GlobeNewsWire

GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Ni...

1 year ago - GlobeNewsWire

GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Ni...

1 year ago - GlobeNewsWire

About XAIR

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc. and changed its ... [Read more...]

Industry
Medical Devices
CEO
Steven Lisi
Employees
23
Stock Exchange
NASDAQ
Ticker Symbol
XAIR
Full Company Profile

Financial Performance

In 2019, Beyond Air's revenue was $1.39 million, a decrease of -82.00% compared to the previous year's $7.72 million. Losses were -$19.94 million, 204.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Beyond Air stock is "Buy." The 12-month stock price forecast is 13.25, which is an increase of 143.12% from the latest price.

Price Target
$13.25
(143.12% upside)
Analyst Consensus: Buy